Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18

Benzinga · 5d ago
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $14 to $18.